Table 6.
Postoperative survival analysis of patients with different EGFR and TTF-1 expression status
Groups | Total
|
Stages III–IV
|
||||
---|---|---|---|---|---|---|
Hazard ratio | Confidence interval (95%) | P-value | Hazard ratio | Confidence interval (95%) | P-value | |
EGFR | 0.636 | 0.369–1.097 | 0.104 | 0.644 | 0.352–1.178 | 0.153 |
TTF-1 | 0.743 | 0.391–1.413 | 0.365 | 0.479 | 0.241–0.954 | 0.036 |
EGFR(+)/TTF-1(+) vs others | 0.574 | 0.326–1.009 | 0.054 | 0.571 | 0.305–1.067 | 0.079 |
EGFR(+)/TTF-1(−) vs others | 1.644 | 0.512–5.282 | 0.404 | 1.642 | 0.503–5.365 | 0.412 |
EGFR(−)/TTF-1(+) vs others | 1.421 | 0.835–2.417 | 0.195 | 1.098 | 0.601–2.004 | 0.762 |
EGFR(−)/TTF-1(−) vs others | 1.223 | 0.597–2.505 | 0.583 | 2.116 | 0.975–4.590 | 0.058 |
EGFR(+)/TTF-1(+) vs EGFR(−)/TTF-1(−) | 1.706 | 0.752–3.869 | 0.201 | 2.616 | 1.085–6.306 | 0.027 |
Abbreviations: EGFR, epidermal growth factor receptor; TTF-1, thyroid transcription factor-1.